Patents by Inventor Bernhard Neises
Bernhard Neises has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7342029Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF?B is involved.Type: GrantFiled: July 22, 2005Date of Patent: March 11, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, Gerhard Jaehne, Joerg Habermann
-
Publication number: 20050282866Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF?B is involved.Type: ApplicationFiled: July 22, 2005Publication date: December 22, 2005Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Olaf Ritzeler, Hans Stilz, Bernhard Neises, Gerhard Jaehne, Joerg Habermann
-
Publication number: 20040209868Abstract: Compounds of the formula I 1Type: ApplicationFiled: May 11, 2004Publication date: October 21, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, Gerhard Jaehne, Jorg Habermann
-
Patent number: 6667334Abstract: The present invention relates to imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.Type: GrantFiled: March 12, 2001Date of Patent: December 23, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Bernhard Neises, Volkmar Wehner, Hans Ulrich Stilz
-
Publication number: 20030119820Abstract: Compounds of the formula I 1Type: ApplicationFiled: October 4, 2002Publication date: June 26, 2003Applicant: Aventis Pharma Deutschland GmbHInventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, Gerhard Jaehne, Jorg Habermann
-
Patent number: 6358978Abstract: Compounds of formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF&kgr;B is involved.Type: GrantFiled: June 22, 2000Date of Patent: March 19, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, William Jerome Bock, Jr., Armin Walser, Gary A. Flynn, Jörg Habermann, Gerhard Jähne
-
Patent number: 6355673Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involvedType: GrantFiled: October 18, 2000Date of Patent: March 12, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Günter Billen
-
Patent number: 6159995Abstract: Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.Type: GrantFiled: May 8, 1998Date of Patent: December 12, 2000Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Gunter Billen
-
Patent number: 6130315Abstract: This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.Type: GrantFiled: August 24, 1998Date of Patent: October 10, 2000Assignee: Merrell Pharmaceuticals Inc.Inventors: H. Michael Kolb, Joseph P. Burkhart, Michael J. Jung, Fritz E. Gerhart, deceased, Eugene L. Giroux, Bernhard Neises, Daniel G. Schirlin
-
Patent number: 5849866Abstract: This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignee: Merrell Pharmaceuticals Inc.Inventors: H. Michael Kolb, Joseph P. Burkhart, Michel J. Jung, Fritz E. Gerhart, deceased, Eugene L. Giroux, Bernhard Neises, Daniel G. Schirlin
-
Patent number: 5563156Abstract: This invention relates to novel polyfluorinated alkyl derivatives of certain tripeptides, to the methods for their preparation, the intermediates therefore, to their use in inhibiting thrombin and lung tryptase and in their end-use application as anti-coagulants useful in treating thrombophlebitis and coronary thrombosis and in the treatment of asthma.Type: GrantFiled: May 19, 1995Date of Patent: October 8, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Bernhard Neises, Axel Ganzhorn, C eline Tarnus, Robert J. Broersma, Jr.
-
Patent number: 5498779Abstract: This invention relates to novel polyfluorinated alkyl derivatives of certain tripeptides, to the methods for their preparation, the intermediates therefore, to their use in inhibiting thrombin and lung tryptase and in their end-use application as anti-coagulants useful in treating thrombophlebitis and coronary thrombosis and in the treatment of asthma.Type: GrantFiled: May 22, 1995Date of Patent: March 12, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Bernhard Neises, Axel Ganzhorn, Celine Tarnus, Robert J. Broersma, Jr.
-
Patent number: 5496927Abstract: This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.Type: GrantFiled: May 25, 1994Date of Patent: March 5, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: H. Michael Kolb, Joseph P. Burkhart, Michel J. Jung, Fritz E. Gerhart, deceased, Eugene L. Giroux, Bernhard Neises, Daniel G. Schirlin
-
Patent number: 5391705Abstract: This invention relates to novel polyfluorinated alkyl derivatives of certain tripeptides, to the methods for their preparation, the intermediates therefore, to their use in inhibiting thrombin and lung tryptase and in their end-use application as anti-coagulants useful in treating thrombophlebitis and coronary thrombosis and in the treatment of asthma.Type: GrantFiled: February 18, 1994Date of Patent: February 21, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Bernhard Neises, Axel Ganzhorn, Celine Tarnus, Robert J. Broersma, Jr.